Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next?

Minerva Neurosciences, Inc. (NASDAQ:NERV)’s share price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.80 and traded as low as $2.58. Minerva Neurosciences shares last traded at $2.60, with a volume of 18,036 shares changing hands.

Wall Street Analyst Weigh In

NERV has been the topic of a number of analyst reports. StockNews.com started coverage on shares of Minerva Neurosciences in a research report on Wednesday. They issued a “sell” rating on the stock. HC Wainwright reduced their price objective on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.

Minerva Neurosciences Trading Down 1.9 %

The stock has a 50 day simple moving average of $2.76 and a 200 day simple moving average of $2.80. The firm has a market capitalization of $18.18 million, a PE ratio of -0.58 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, equities analysts anticipate that Minerva Neurosciences, Inc. will post -2.26 earnings per share for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.